Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised,placebo-controlled trials |
| |
| Institution: | 1. Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark;2. Department of Clinical Pharmacology, Bispebjerg-Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark;3. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;4. Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark;5. Steno Diabetes Center Copenhagen, Gentofte, Denmark;1. Department of Cardiology, The First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang 110001, China;2. Department of Cardiology, Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China;3. Department of Neurology, The First Hospital of China Medical University, 155 Nanjing North Street, Heping District, Shenyang, 110001, China;4. Department of Cardiology, East Hospital, Tongji University School of Medicine, 150 Jimo Road, Pudong District, Shanghai 200120, China;1. Diabetes and Obesity Research Group, University of Exeter Medical School, Exeter, UK;2. Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;3. Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark;4. RD&E NHS Foundation Trust, Exeter, UK;5. NIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK |
| |
| Abstract: | AimsSevelamer has been reported to have anti-oxidative and anti-inflammatory effects as well as effects on glycaemic control and plasma lipids. The aim of this study was to determine the effects of one-week treatment with sevelamer on oxidative nucleic acid modifications and inflammation markers.MethodsTwo double-blinded studies including 30 patients with type 2 diabetes (T2D) and 20 healthy individuals were conducted. Participants were randomised to one week of treatment with sevelamer (1600 mg three times daily) or placebo. RNA and DNA oxidation, measured by urinary excretion of 8-oxo-7,8-dihydroguanosine(8-oxoGuo) and (8-oxo-7,8-dihydro-2′-deoxyguanosine(8-oxodG), and markers of inflammation were determined before and after the intervention.ResultsIn patients with T2D there was no significant placebo-corrected reduction in 8-oxoGuo or 8-oxodG. However, a reduction in 8-oxoGuo was observed within the group treated with sevelamer (∆8-oxoGuo/creatinine (medianIQR]): −0.04 −0.24; 0.01] nmol/mmol, p = 0.02). A sevelamer-mediated reduction in interleukin-2 (p = 0.04) and a trend towards reduction in interleukin-6 (p = 0.053) were found in patients with T2D.ConclusionsThis study reveals a potential effect of sevelamer treatment on inflammation and possible oxidative RNA modifications. The potential protective effects of sevelamer in terms of cardiovascular disease in patients with T2D need further investigation. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
